Compare Main Street Capital Corporation (MAIN) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Summit Therapeutics Inc — how do they compare? Main Street Capital Corporation trades at $58.4 (market cap $5.52B), while Summit Therapeutics Inc trades at $15.25 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 2.2× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays a 5.39% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MAIN | SMMT | |
|---|---|---|
Market Cap | $5.52B | $12.06B |
Sector | Financials | Health |
52-Week High | $67.54 | $26.98 |
52-Week Low | $49.63 | $12.55 |
Dividend Yield | 5.39% | — |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $59.10, up 0.99% with a bullish technical outlook. The stock shows strong fundamentals with an 80.77% net income margin and 14.92% ROE, though Q2 2026 earnings missed estimates. Recent news highlights MAIN's dividend reliability amid sector challenges, with the company maintaining payouts while peers face cuts. Technical indicators show bullish moving averages but overbought RSI levels near resistance at $59-60.
MAIN offers stable income with consistent dividends but faces headwinds from declining revenue projections ($592M in 2025 to $559M in 2026). Analyst consensus is cautious with 78.57% hold ratings and a $56.67 price target below current levels. Key risks include BDC sector pressure and expense growth impacting earnings coverage.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
